首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy and safety of bevacizumab in recurrent sex cord‐stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group
Authors:Jubilee Brown MD  William E. Brady PhD  Julian Schink MD  Linda Van Le MD  Mario Leitao MD  S. Diane Yamada MD  Koen de Geest MD  David M. Gershenson MD
Affiliation:1. Department of Gynecologic Oncology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York;3. Department of Gynecologic Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois;4. University of North Carolina School of Medicine, Chapel Hill, North Carolina;5. Department of Surgery, Memorial Sloan‐Kettering Cancer Center, New York, New York;6. Department of Obstetrics/Gynecology, NorthShore University Health System, Lake Forest, Illinois;7. Department of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
Abstract:
Keywords:bevacizumab  Gynecologic Oncology Group  stromal ovarian tumors  survival
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号